

Convergent Approaches for the Synthesis of the Anti-tumoral Peptide, Kahalalide F. Study of Orthogonal Protecting Groups

Carolina Gracia,^{†,δ} Albert Isidro-Llobet,^{†,δ} Luis J. Cruz,[†] Osvaldo Acosta,[†] Mercedes Álvarez^{†,β}, Carmen Cuevas[‡], Ernest Giralt^{†,§} and Fernando Albericio^{†,§,}*

[†] These authors contributed equally to the study

^δ Institute for Research in Biomedicine, Barcelona Science Park, University of Barcelona, 08028-Barcelona, Spain

^β Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028-Barcelona, Spain

[‡] PharmaMar S.A.U., 28770-Colmenar Viejo (Madrid), Spain

[§] Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1, 08028-Barcelona, Spain

DATE RECEIVED _____

Convergent Synthesis of Kahalalide F

To whom correspondence should be addressed: Fernando Albericio (albericio@pcb.ub.es)

Abstract

Kahalalide compounds are peptides that are isolated from a Hawaiian herbivorous marine species of mollusc, *Elysia rufescens*, and its diet, the green alga *Bryopsis sp.* Kahalalide F and its synthetic analogues are the most promising compounds of the Kahalalide family because they show anti-tumoral activity. Linear solid-phase syntheses of Kahalalide F have been reported. Here we describe several new improved synthetic routes based on convergent approaches with distinct orthogonal protection schemes for the preparation of Kahalalide analogues. These strategies allow a better control and characterization of the intermediates because more reactions are performed in solution. Five derivatives of Kahalalide F were synthesized using several convergent approaches.

KEYWORDS. Anti-tumoral compounds, Cyclic peptides, Desipeptides, Didehydroamino acids, Marine origin products, Natural products, Orthogonal protecting groups, Solid-phase synthesis,

Introduction

Kahalalide compounds are peptides that are isolated from a Hawaiian herbivorous marine species of mollusc, *Elysia rufescens* and its diet, the green alga *Bryopsis sp.* Kahalalide F¹ and analogues are the most promising compounds of the Kahalalide family because of their anti-tumoral activities.² Thus, Kahalalide F alters the function of the lysosomal membrane, a characteristic that distinguishes it from all other known anti-tumour agents. This compound also inhibits TGF- α expression, blocks intracellular signalling pathways downstream of EGF and ErbB2 receptor family and induces non-p53-mediated apoptosis.³ Recent studies demonstrate that Kahalalide F induces cell necrosis *in vivo* (oncosis) and shows selectivity for tumour compared with healthy cells *in vitro*.⁴ Its activity is independent of multi-drug resistance (MDR) expression.⁵

Kahalalide F is currently undergoing Phase II clinical trials in various solid tumours: melanoma, non-small cell lung cancer, and hepatocellular carcinoma. A Phase II trial for the treatment of patients with severe psoriasis is also ongoing.⁶

Members of the Kahalalide F family, which are *head-to-side chain* cyclodepsipeptides, have a complex structure, comprising six amino acids, among these the *Z*-didehydro- α -aminobutyric acid (ZDhb) (formed from dehydration of a Thr residue), as a cyclic part between the carboxylic acid of a L-Val 1 and the secondary alcohol of the *Da*Thr 6, and an exocyclic chain of seven amino acids with a terminal aliphatic/fatty acid group (R) (Figure 1).^{1,7,8,9} Compounds in which R is a methylhexanoic acid are of greatest interest.¹⁰




Figure 1. Structure of Kahalalide F.

Linear solid-phase syntheses of Kahalalides involving cyclization and final deprotection performed in solution have been described.^{8,11} However, synthetic routes for Kahalalide compounds are still required. Here we report several new convergent strategies for the synthesis of Kahalalide F derivatives. Convergent strategies are defined as those in which peptide fragments are coupled to give the desired target molecule.^{12,13,14,15} The condensation of peptide fragments should lead to fewer problems in the isolation and purification of intermediates. The difference between the condensation product desired and the segments themselves, in terms of molecular size and chemical nature, should be sufficiently pronounced so as to permit their separation relatively easily. Several orthogonal protecting schemes have been used in these strategies.¹⁶

Although solid-phase strategies are crucial for peptide synthesis,^{12b,17, 18,19,20} the method of choice for a convergent strategy involves a combination of solid-phase and solution chemistries. Thus, protected peptides

are prepared in solid-phase and then combined in solution.^{21,22} a Paradigm of this strategy is the large-scale commercial production of enfuvirtide (T-20 or Fuzeon), a 36-amino acid peptide.²³


Results and Discussion

To render Kahalalide F a 14-building block peptide [13 amino acids and the methylhexanoic acid], the most convenient synthetic strategy involves dividing the peptide in two fragments, the *N*-terminal and the fragment containing the cycle. Fragment composition can be modified in order to optimize condensation yields and minimize side reactions, such as epimerization.




Scheme 1. Convergent strategy for the synthesis of Kahalalide F analogues. AAA, BBB, CCC, DDD, and EEE are amino acid residues.


The preparation of the *N-Component* requires cyclization in solution and therefore the *N*-protection should also be kept during the cleavage of the lineal fragment from the resin.

Solid-phase synthesis of protected peptides requires a resin that facilitates the release of the peptide without removing the side-chain protecting groups, which are removed as the last step of the synthesis.^{12a,13,14} In this regard, the *t*Bu-based protecting groups are highly convenient because they are removed with high concentrations of trifluoroacetic acid (TFA) in the presence of scavengers and are stable to piperidine, used to remove the α -amino protecting group, and to low concentrations of TFA. The super-acid-labile chlorotriptyl chloride polystyrene (CTC, Barlos, ) resin allows the release of peptides with 1-2 % of TFA in CH₂Cl₂ or even with trifluoroethanol or hexafluoroacetone solutions.²⁴ An additional advantage of the CTC resin is that its hindered structure minimizes the formation of the diketopiperazines (DKP) during removal of the temporal protecting group of the second amino acid.^{25,26}

General Strategies: Three sets of fragments were prepared. Schemes 2 and 3 show the *C-Components* and their complementary *N-Components* synthesized.



Scheme 2. *C*-Components synthesized



Scheme 3. *N*-Components synthesized

A priori, the main advantage of strategy 1 is that the hardly racemizable Pro is the *C*-terminal amino acid for the *C*-Component. In contrast, the advantage of strategies 2 and 3 is that the *N*-Component does not contain any side-chain protecting group and therefore a level of protecting groups can be avoided for these fragments.


All fragments were synthesized on the CTC-resin, starting with a limited incorporation of the first 9-fluorenylmethoxycarbonyl (Fmoc)-amino acid in the presence of *N,N*-diisopropylethylamine (DIEA).²⁷ The remaining resin chloride functions were capped with methanol (MeOH) to prevent the formation of tertiary amines after treatment with the piperidine used to remove the Fmoc group.²⁸ The Fmoc-protecting group was

removed with piperidine–*N,N*-dimethylformamide (DMF) (1:4) and the peptide chain was elongated with *N,N'*-diisopropylcarbodiimide (DIPCDI) and 1-hydroxybenzotriazole (HOBt) as coupling reagents. Finally, the peptides were cleaved from the resin with TFA–CH₂Cl₂ (1:99), characterized by HPLC and ESMS, and purified by semi-preparative HPLC when necessary.

Synthesis of the *N*-Components: The ZDhb moiety was incorporated through the dipeptide allyloxycarbonyl (Alloc)-Phe-ZDhb-OH, which is much faster than incorporating sequentially Thr and Phe and performing the dehydration of Thr to ZDhb on solid phase.^{8,11}

Four synthetic strategies were used to prepare the three distinct *N*-Components (Scheme 4). All the strategies are based on the solid-phase synthesis of a branched peptide using a tri- or tetra-orthogonal protecting scheme and subsequent cyclization and deprotection of the *N*-terminal function in solution. Strategy 1, which produces the *N*-Component 1, follows the procedure previously described^{8,11} and starts with the incorporation of Fmoc-D-Val-OH on the CTC resin, followed by elongation until the D-*a*Ile⁷, esterification of the β-hydroxyl of the *Da*Thr with Alloc-Val-OH. The incorporation of protected Orn(Boc) residue on the main chain is then followed by the incorporation of the Alloc-Phe-ZDhb-OH on the branched one. Strategy 3, which leads to the *N*-Component 2, is similar to 1, but elongation is stopped after incorporation of *Da*Ile⁷. In strategies 2 and 4, which yield *N*-Component 1 and *N*-Component 3 respectively, synthesis starts with the incorporation of the Alloc-Phe-ZDhb-OH onto the CTC resin (see below for the discussion of the strategy).

This study addressed: (i) the most convenient strategy in terms of coupling yield and racemization of the *C*-terminal amino acid of the *C*-Component (strategies 1 or 2 vs. 3 and 4); (ii) for strategies 1 and 2 (*N*-Component 1), the best semi-permanent protecting group [Fmoc, *p*-nitrobenzyloxycarbonyl (*p*NZ)^{11,29,30} in strategy 1 and Alloc in the 2]³¹ for the *N*^α-amino of Orn, taking into account that the *t*-butoxycarbonyl (Boc) group is reserved as permanent protecting group for the *N*^ε-amino of the same Orn; and (iii) whether the dipeptide Alloc-Phe-ZDhb-OH is a good starting point for the elongation of the peptidic chain (strategies 2 and 4) when compared with the traditional Fmoc-D-Val-OH⁴.



Scheme 4. Strategies for the syntheses of the cyclic fragment.

As protecting group for the N^α -amino of Orn, Fmoc, Alloc, and the recently described pNZ^{11,29,30} was examined (Scheme 4, strategies 1 and 2) as well as Boc (Scheme 4, strategies 3 and 4). Alloc was removed

by Pd(0) in rather neutral conditions in the presence of a scavenger of the allyl carbocations.³² *p*NZ is orthogonal to the most common solid-phase peptide synthesis (SPPS) protecting groups such as *t*-butyl (*t*Bu)/Boc, Fmoc, and Alloc. It was removed under simple and practical neutral conditions by SnCl₂ in the presence of catalytic amounts of acid.²⁹ When the Fmoc group (strategy 1) was removed under the classical conditions piperidine–DMF (1:4), the major product was the linear peptide, which formed by aminolysis of the ester bond.³³ However, the use of diethylamine (DEA) (30 eq of DEA for 90 min at 25 °C) minimized the undesired side-reaction. In this case, although no opening of the cycle was detected, some starting product (around 5%)* remained in the reaction crude. In the same strategy, the use of *p*NZ-Orn(Boc)-OH instead of Fmoc-Orn(Boc)-OH was examined. The ester bond was stable to the SnCl₂ treatment used to remove *p*NZ.

Furthermore, the same stability was achieved when the Alloc group (Scheme 4, strategy 2) was removed with Pd(0) in the presence of triethylsilane (TES). To use Alloc as a semi-permanent protecting group, the classical strategy 1 used for the synthesis of Kahalalide F could not be followed because it would have been necessary to remove Alloc as *N*^α-protecting group of the Phe in the presence of the semi-permanent protecting group of the Orn (Scheme 4, Strategy 1). Thus, a new strategy to circumvent this problem was assayed. This strategy began with the incorporation of Alloc-Phe-ZDhb-OH as the first building block to the CTC resin using the same conditions required for the introduction of protected amino acids (Scheme 4, Strategy 2). The peptide chain was elongated using Fmoc for the α-amino protection of DVal, DaIle, DaThr, and Dalle, and Alloc** for the Orn(Boc). This new strategy worked well in terms of cyclization yield and in addition showed two key advantages. Due to the defect of first protected building block required for the incorporation onto the CTC resin, a smaller amount of the precious Alloc-Phe-ZDhb-OH was required compared with strategy 1, in which the dipeptide was introduced in excess. Secondly and more importantly,

* The starting peptide contains a Fmoc group, which makes a difference in the ε of both compounds and therefore difficult the yield calculation.

** In this strategy the Orn(Boc) could be also introduced as *p*NZ-Orn(Boc)-OH.

ZDhb does not show chirality and therefore no epimerization occurred during the cyclization step, which is the most prone for inducing racemization.

In strategies 3 and 4, and as the *N-Components* 2 and 3 did not contain any side-chain protecting group, the Boc group was used as *N*^α-amino protecting group of the *N*-terminal residue (*DaIle*⁷ in strategy 3 and *DaThr* in the 4). In addition to the full stability of the lactone bond to the conditions (TFA) used to remove that protecting group, the main advantages associated with the use of the Boc group were that the reagent to remove this group as well as the side-products formed were volatile and therefore could be removed by simple evaporation.

Condensation of linear and cyclic fragments: First of all, and using *C*- and *N-Components* as models, we screened the coupling methods [DIPCDI/7-aza-1-hydroxybenzotriazole (HOAt) (1.5 eq. each); 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDC)/HOBT (3 eq. each); EDC/HOBT/*N,N*-dimethylaminopyridine (DMAP) (4 eq., 4eq., 0.4 eq.); (7-azabenzotriazol-1-yloxy)-tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP)/DIEA (1 eq., 3 eq.) + PyAOP (1 eq after 1h), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo-[4,5-*b*]pyridinium hexafluorophosphate 3-oxide (HATU)/DIEA (1 eq., 3 eq.)] . On the basis of this screening, we concluded that the method based on PyAOP gave the best results in terms of yields and the absence of side-products in the HPLC chromatograms (Table 1). Phosphonium derivatives such as PyAOP are more convenient for slow couplings compared with aminium/uronium reagents such as HATU, since the latter can terminate the peptide chain through a guanidination reaction.³⁴ Furthermore, PyAOP contains HOAt, which is the most reactive benzotriazole.³⁵

Each linear *C-Component* was then condensed with its corresponding *N-Component* in solution phase using PyAOP and DIEA. The three protected peptides obtained were treated with TFA–H₂O (9:1) to remove the Boc and *t*Bu groups and yielded Kahalalide F.

A range of results were obtained depending on which *C*- and *N*-terminal amino acids of the *C*- and *N-Components*, respectively, were involved. From the point of view of the purity of the final product, the strategies that involved the concourse of *C*- and *N-Components* 1 and 2 were superior to that corresponding to fragments 3. This can be explained because the latter involves coupling between two hindered β-branched

amino acids (*Dalle* and *DaThr*). Furthermore, *DaThr* is part of the cycle, which may also impair the coupling of the protected peptide. The *C*- and *N*-Component 1 strategy also gave slightly superior results.

Conditions	% of final product in the HPLC
DIPCDI/HOAt (1.5 eq, 1.5 eq)	47 % (t= 48 h)
EDC/HOBt/DMAP (4 eq, 4 eq, 0.4 eq)	16 % (t= 6h), 23 % (t=20h)
PyAOP/DIEA (1eq, 3 eq) + 1 eq PyAOP at t= h	35 % (t= 30 min) 54 % (t= overnight)
HATU/DIEA (1eq, 3 eq) + 1 eq PyAOP at t= 3 h	43 % (t= 30 min) 49% (t=overnight)
EDC/HOBt (3 eq, 3 eq)	5.8% (t= 30 min) 53% (t= overnight)

Table 1. Screening of C and N Components coupling methods.




Figure 2. HPLC analysis of the solution coupling between *C*- and *N*-Components 1 over time. Linear gradient of MeCN (+0.036% TFA) into H₂O (+0.045% TFA), from 30% to 100% in 15 min.

Furthermore, when the *C*-terminal amino acids of the *C*-Component were Orn [*C*-Component 2 and *N*-Component 2 (Strategy 3, Scheme 4)] or *Dalle* [*C*-Component 3 and *N*-Component 3 (Strategy 4, Scheme 4)],

epimerisation of these amino acids was observed [4 % for the case of Orn (Figure 3) and more than 10% for DaIle (data no shown)].³⁶ However, when the C-terminal amino acid of the linear fragment was D-Pro [C- and N-Components 1 (Strategy 1 or 2, Scheme 4)], epimerisation was not observed (Figure 4). These results were obtained by comparing the HPLC crudes of the Kahalalide F compounds synthesized by the strategies and the three epimers, which were also synthesized by a stepwise strategy (substitution of DPro for LPro, of LOrn for DOrn, and of DaIle for Ile). Our observations confirm that, due to its cyclic secondary amino function, Pro is less prone to racemize during fragment coupling.




Figure 3. HPLC analysis of the Boc protected Kahalalide F prepared from C- and N-Components 2 (up and red) compared with the (DOrn⁸)-Kahalalide F (down and blue). Linear gradient of MeCN (+0.036% TFA) into H₂O (+0.045% TFA), from 30% to 100% in 15 min.




Figure 4. HPLC analysis of the Boc protected Kahalalide F prepared from C- and N-Components 1 (green) compared with the (LPro⁹)-Kahalalide F (red). Linear gradient of MeCN (+0.036% TFA) into H₂O (+0.045% TFA), from 30% to 100% in 15 min.

Conclusions

Here we developed several convergent strategies for the synthesis of the analogues of the antitumor peptide Kahalalide F. The best approaches were those in which the *C*-terminal amino acid of the *C-Component* is DPro because it avoids epimerization during the coupling of the fragment in solution. The choice of the semi-permanent protecting group for the *N*^α-amino of Orn-protecting groups requires additional discussion. Thus, the use of the less common groups, *p*NZ, and Alloc, which assure total stability of the lactone, implies the concourse of metallic cations or metals, which may demand a purification step before the final fragment coupling. Furthermore, the Fmoc group requires fine-tuning of the experimental process, which can be detrimental for the development of a large scale process in which conditions may be more difficult to control. The use of the *N-Component* prepared by strategy 2 (Scheme 4) shows several advantages because it allows the preparation of Kahalalide F without risk of epimerization during cyclization and uses lower amounts of the precious Alloc-Phe-ZDhb-OH.

Experimental Section

General Procedures. Cl-TrtCl-resin, Protected Fmoc-amino acid derivatives, HOBt, HOAt were purchased from different sources as well as DIPEA, DIPCDI, EDC·HCl, piperidine, TFA, DMF, MeCN (HPLC grade) and CH₂Cl₂. All commercial reagents and solvents were used as received with the exception of DCM, which was passed through an alumina column to remove acidic contaminants.

*p*NZ-Orn(Boc)-OH was prepared as described previously²⁹ and Alloc-amino acids as essentially described by Dangles *et al.* and Cruz *et al.*^{37, 38} Alloc-ZDhb-Phe-OH was prepared as before³⁹

Solid-phase syntheses were performed in polypropylene syringes (10-50 mL), each fitted with a polyethylene porous disc. Solvents and soluble reagents were removed by suction. The Fmoc group was removed with piperidine–DMF (2:8, v/v) (1 x 2 min, 2 x 10 min). Washings between deprotection, coupling, and, again, deprotection steps were performed with DMF (5 x 0.5 min) and CH₂Cl₂ (5 x 0.5 min) using 10

mL solvent/g resin each time. Peptide synthesis transformations and washings were done at 25 °C. Syntheses carried out on solid-phase were controlled by HPLC of the intermediates obtained after cleaving an aliquot (approx. 2 mg) of the peptidyl-resin with TFA–H₂O (1:99) for 1 min. HPLC reversed-phase columns Symmetry™ C₁₈ 4,6 x 150 mm, 5 μm (column A) and Symmetry300™ C₁₈ 4,6 x 50 mm, 5 μm (column B) were used. Analytical HPLC was performed on an instrument comprising two solvent delivery pumps, automatic injector dual wavelength detector, and system controller (Breeze V3.20) and on an instrument comprising two solvent delivery pumps, automatic injector and a variable wavelength detector (Photodiode Array). UV detection was at 215 or 220 nm, and linear gradients of MeCN (+0.036% TFA) into H₂O (+0.045% TFA), from 30% to 100% in 15 min.

MALDI-TOF and ES-MS analysis of peptide samples were performed using ACH matrix,. Peptide-resin samples for amino acid analysis were hydrolyzed in 12 N aqueous HCl-propionic acid (1:1), at 155 °C for 1-3 h and peptide-free samples were hydrolyzed in 6 N aqueous HCl at 155 °C for 1 h.

The “&” symbol is used in the nomenclature for cyclic peptides and precursors.⁴⁰ The appearance of “&” in a given position of the one-line formula indicates the location of one end of a chemical bond and the second “&” the point to which this bond is attached. Thus, “&” represents the start or the end of a chemical bond, which is ‘cut’ with the aim to facilitate the view of a complex formula. In this way, two “&” symbols indicate one chemical bond.

N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& from Fmoc-Orn(Boc)-OH:

H-D-Val-O-TrtCl-resin (1):

Cl-TrtCl-resin (1 g, 1.64 mmol/g) was placed in a 20 mL polypropylene syringe fitted with a polyethylene filter disk. The resin was then washed with CH₂Cl₂ (5 x 0.5 min), and a solution of Fmoc-D-Val-OH (238 mg, 0.7 mmol, 0.43 equiv) and DIPEA (0.41 mL) in CH₂Cl₂ (2.5 mL) was added. The mixture was then stirred for 15 min. Extra DIPEA (0.81 mL, total 7 mmol) was added and the mixture was stirred for an additional 45 min. The reaction was stopped by adding MeOH (800 μL) and stirring for 10 min. The

Fmoc-D-Val-O-TrtCl-resin was subjected to the following washings/treatments with CH₂Cl₂ (3 x 0.5 min), DMF (3 x 0.5 min), piperidine as indicated in General Procedures, and DMF (5 x 0.5 min). The loading was 0.50 mmol/g, as calculated by Fmoc determination.

*[Fmoc-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-O-TrtCl-resin][Alloc-Val&] (2):*

Fmoc-D-*allo*-Ile-OH (707 mg, 2 mmol, 4 equiv), Fmoc-D-*allo*-Thr-OH (free hydroxy group) (683 mg, 2 mmol, 4 equiv), and Fmoc-D-*allo*-Ile-OH (707 mg, 2 mmol, 4 equiv) were added sequentially to the above obtained H-D-Val-O-TrtCl-resin (**1**) using DIPCDI (310 μ L, 2 mmol, 4 equiv) and HOBt (307 mg, 2 mmol, 4 equiv) in DMF (2.5 mL). In all cases, after 90 min of coupling, the ninhydrin test was negative. Removal of Fmoc group and washings were performed as described in General Procedures. Alloc-Val-OH (502 mg, 2.5 mmol, 5 equiv) was coupled with DIPCDI (387 mg, 2.5 mmol, 5 equiv) in the presence of DMAP (30.6 mg, 0.25 mmol, 0.5 equiv) and DIPEA (88 μ L, 0.5 mmol, 1 equiv) for 45 min. This coupling was repeated twice in the same conditions. An aliquot of the peptidyl-resin was treated with TFA and the HPLC (R_t 14.2 min, column A) of the crude obtained after evaporation showed a purity of > 98%. ESMS, calcd. for C₄₅H₆₃N₅O₁₁, 849.45. Found: m/z 850.1 [M+H]⁺, 871.9 [M+Na]⁺.

*[Fmoc-Orn(Boc)-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-O-TrtCl-resin][Alloc-Val&] (3):*

The Fmoc group of the peptide resin (**2**) was removed and Fmoc-Orn(Boc)-OH (912 mg, 2 mmol, 4 equiv) was added using DIPCDI (310 μ L, for 2.0 mmol and 4 equiv; and 388 μ L, for 2.5 mmol and 5 equiv) and HOBt (307 mg, for 2.0 mmol and 4 equiv; and 395 mg, for 2.5 mmol and 5 equiv) for 90 min. Ninhydrin test after the incorporation was negative. An aliquot of the peptidyl-resin was treated with TFA and the HPLC (R_t 12.8 min, column A) of the crude obtained after evaporation showed a purity of 90 %. ESMS, calcd. for C₅₆H₈₁N₇O₁₄, 1,063.58. Found: m/z 1,086.77 [M+Na]⁺.

*[Fmoc-Orn(Boc)-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-O-TrtCl-resin][Alloc-Phe-ZDhb-Val&] (4):*

The Alloc group of the peptide resin (**3**) was removed with Pd(PPh₃)₄ (58 mg, 0.05 mmol, 0.1 equiv) in the presence of PhSiH₃ (617 μL, 5 mmol, 10 equiv), followed by washings with diethyldithiocarbamate 0.02 M (3 x 15 min). Alloc-Phe-ZDhb-OH (666 mg, 2 mmol, 4 equiv) and HOAt (273 mg, 2 mmol, 4 equiv) were dissolved in DMF (1.25 mL) and added to peptidyl-resin. DIPCDI (310 μL, 2 mmol, 4 equiv) was then added and the mixture was stirred for 5 h. The ninhydrin test was negative. After washings with DMF and CH₂Cl₂, an aliquot of the peptidyl-resin was treated with TFA–H₂O (1:99) for 1 min and the product was characterized by MALDI-TOF-MS: calcd. for C₆₈H₉₅N₉O₁₆, 1,293.69 Found: *m/z* 1,294.35 [M+H]⁺, 1,316.39 [M+Na]⁺, 1,333.34 [M+K]⁺.

[Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-OH][H-Phe-ZDhb-Val&] (**5**):

The Alloc group of the peptide resin (**4**) was removed with Pd(PPh₃)₄ (58 mg, 0.05 mmol, 0.1 equiv) in the presence of PhSiH₃ (617 μL, 5 mmol, 10 equiv), the resin was washed with sodium diethyldithiocarbamate in DMF 0.02 M (3 x 15 min) and the protected peptide was cleaved from the resin by TFA–CH₂Cl₂ (1:99) (5 x 30 sec). The filtrate was collected on H₂O (4 mL) and the H₂O was partially removed under reduced pressure. MeCN was then added to dissolve solid that formed during the removal of H₂O, and the solution was lyophilized to give 700 mg of title compound (578 μmol, 99% yield) of the title compound with a purity of > 91 % as checked by HPLC (Column A, *R*_t 8.59 min)], which was used without further purification. MALDI-TOF-MS, calcd. for C₆₄H₉₁N₉O₁₄, 1,209.67. Found: *m/z* 1,210.45 [M+H]⁺, 1,232.51 [M+Na]⁺, 1,248.45 [M+K]⁺.

Fmoc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (**6**):

The protected peptide (**5**) was dissolved in CH₂Cl₂ (580 mL, 1 mM), and HOBt (137 mg, 2.3 mmol) dissolved in the minimum volume of DMF to dissolve HOBt, DIPEA (302 μL, 1.73 mmol, 3 equiv), and DIPCDI (356 μL, 2.3 mmol, 4 equiv) were added. The mixture was stirred for 1 h, and the course of the cyclization step was then checked by HPLC (column A, *R*_t 12.4 min). The solvent was removed by

evaporation under reduced pressure and the product was used without further purification. MALDI-TOF-MS, calcd. for C₆₄H₈₉N₉O₁₃, 1,191.66. Found: m/z 1,092.17 [M+H]⁺, 1,214.14 [M+Na]⁺, 1,230.10 [M+K]⁺.

H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1):

The protected peptide (**6**) (50 mg, 42 μmol) was dissolved in DMF (5 mL), then DEA (130 μL, 30 equiv) was added and the mixture was stirred for 90 min. The solvent was removed by evaporation under reduced pressure. The crude product was purified by HPLC (Symmetry C8 5 μm, 30 x 100 mm), linear gradient of MeCN (30% to 75% in 15 min) MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm. The product was characterized by HPLC (R_t 8.7 min, Condition A) and MALDI-TOF-MS, calcd. C₄₉H₇₉N₉O₁₁, 969.59. Found: m/z 970.87 [M+H]⁺, 870.78 [M-Boc]⁺.

N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& from pNZ-Orn(Boc)-OH:

pNZ-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (7):

The synthesis was performed in the same way as for compound **6**, but Fmoc-Orn(Boc)-OH was replaced by pNZ-Orn(Boc)-OH.

H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1)

The protected peptide (14.7 mg, 12.8 μmol) was dissolved in 1.6mM HCl in DMF (10 mL), SnCl₂ (3.8 g, 20mmol) was then added and the mixture was stirred until HPLC (Column A) showed the completion of the reaction (1h). The solvent was removed by evaporation under reduced pressure. The crude product was purified by HPLC (Symmetry C8 5 μm, 30 x 100 mm), gradient of MeCN (30% to 75% in 15 min) MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title product (4.8 mg, 4.9 μmol, 40 % yield). The product was characterized by HPLC (R_t 8.2 min, Column A) and for MALDI-TOF-MS: calcd. C₄₉H₇₉N₉O₁₁, 969.59. Found: m/z 992.35 [M+Na]⁺, 870.34 [M-Boc]⁺, 892.34 [M+Na-Boc]⁺.

N-Component 1: H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& from

Alloc-Orn(Boc)-OH:*H-Phe-ZDhb-O-TrtCl-resin (8):*

Cl-TrtCl-resin (1 g, 1.64 mmol/g) was placed in a 20 mL polypropylene syringe fitted with a polyethylene filter disk. The resin was then washed with CH₂Cl₂ (5 x 0.5 min) and a solution of Alloc-Phe-ZDhb-OH (232 mg, 0.7 mmol, 0.42 equiv) and DIPEA (0.41 mL) in CH₂Cl₂ (2.5 mL) was added. This mixture was then stirred for 15 min. Extra DIPEA (0.81 mL, total 7 mmol) was added and the mixture was stirred for an additional 45 min. The reaction was arrested by adding MeOH (800 μL), after stirring for 10 min. The Alloc-Phe-ZDhb-O-TrtCl-resin was subjected to the following washings with CH₂Cl₂ (3 x 0.5 min), DMF (3 x 0.5 min), and the Alloc group was removed with Pd(PPh₃)₄ (58 mg, 0.05 mmol, 0.1 equiv) in the presence of PhSiH₃ (617 μL, 5 mmol, 10 equiv) in CH₂Cl₂. The resin was washed as described in General Procedures. The loading was 0.68 mmol/g, as calculated by Fmoc determination.

[Alloc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-OH][H-Val&] (9):

Fmoc-D-Val-OH (678 mg, 2 mmol, 4 equiv), Fmoc-D-*allo*-Ile-OH (707 mg, 2 mmol, 4 equiv), Fmoc-D-*allo*-Thr-OH (free hydroxy group) (683 mg, 2 mmol, 4 equiv), Fmoc-D-*allo*-Ile-OH (707 mg, 2 mmol, 4 equiv), and Alloc-Orn(Boc)-OH (630 mg, 2 mmol, 4 equiv) were added sequentially to the above obtained H-Phe-ZDhb-O-TrtCl-resin (**8**) using DIPCDI (310 μL, 2 mmol, 4 equiv) and HOBT (307 mg, 2 mmol, 4 equiv) in DMF (2.5 mL). In all cases, after 90 min of coupling, the ninhydrin test was negative. Removal of Fmoc group and washings were performed as described in General Procedures. Fmoc-Val-OH (848.2 mg, 2.5 mmol, 5 equiv) was coupled with DIPCDI (387 mg, 2.5 mmol, 5 equiv) in the presence of DMAP (30.6 mg, 0.25 mmol, 0.5 equiv) and DIPEA (88 μL, 0.5 mmol, 1 equiv) for 45 min. This coupling was repeated twice in the same conditions. After removal of the Fmoc group as described in General Procedures, the protected peptide was cleaved from the resin by TFA-CH₂Cl₂ (1:99) (5 x 30 sec). Filtrate was collected on H₂O (4 mL) and the H₂O was partially removed under reduced pressure. MeCN was then added to dissolve the solid that formed during H₂O removal, and the solution was lyophilized to give 650 mg of target compound (606

μmol , 90 % yield) of the title compound with a purity of > 75 % as checked by HPLC (Column A, R_t 9.93 min). ESMS, calcd. for $\text{C}_{53}\text{H}_{85}\text{N}_9\text{O}_{14}$, 1072.29. Found: m/z 1074.4 $[\text{M}+\text{H}]^+$.

Alloc-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (10):

Peptide **9** (250 mg, 233 μmol) was dissolved in CH_2Cl_2 (240 mL, 1 mM), and HOAt (126 mg, 9.325 mmol, 4 equiv) in the minimum volume of DMF, and DIPCDI (143 μL , 9,325 mmol, 4 equiv) were added. The mixture was stirred for 24 h and the course of the cyclization step was then checked by HPLC (column A, R_t 12.82 min). The solvent was removed by evaporation under reduced pressure and the product was used without further purification. MALDI-TOF-MS, calcd. for $\text{C}_{53}\text{H}_{83}\text{N}_9\text{O}_{13}$, 1,054.28. Found: m/z 1,056.4 $[\text{M}+\text{H}]^+$.

H-Orn(Boc)-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (N-Component 1):

Peptide **10** was dissolved in 10 mL of CH_2Cl_2 , then $\text{Pd}(\text{PPh}_3)_4$ (8 mg, 6,94 μmol , 0.03 equiv) in the presence of PhSiH_3 (94 μL , 763,6 μmol , 3.3 equiv) was added and the mixture was stirred for 90 min. The solvent was removed by evaporation under reduced pressure. The crude product was purified by HPLC (Symmetry C8 5 μm , 30 x 100 mm), linear gradient of MeCN (20% to 80% in 15 min) MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm. The product was characterized by HPLC (R_t 9.19 min, Condition A) and for MALDI-TOF-MS, calcd. $\text{C}_{49}\text{H}_{79}\text{N}_9\text{O}_{11}$, 970.21. Found: m/z 972.1 $[\text{M}+\text{H}]_+$.

C-Component 1: MeHex-D-Val-Thr(*t*Bu)-Val-D-Val-D-Pro-OH

Cl-TrtCl-resin (1 g, 1.64 mmol/g) was placed in a 20 mL polypropylene syringe fitted with a polyethylene filter disk. The resin was then washed with CH_2Cl_2 (5 x 0.5 min), a solution of Fmoc-D-Pro-OH (237 mg, 0.7 mmol, 0.43 equiv) and DIPEA (0.41 mL) in CH_2Cl_2 (2.5 mL) was added, and the mixture was stirred for 15 min. Extra DIPEA (0.81 mL, total 7 mmol) was added and the mixture was stirred for an additional 45 min. The reaction was arrested by stirring the resin in MeOH (800 μL) for 10 min. The Fmoc-D-Pro-O-TrtCl-resin was subjected to the following washings/treatments with CH_2Cl_2 (3 x 0.5 min),

DMF (3 x 0.5 min), piperidine as indicated in General Procedures, and DMF (5 x 0.5 min). The loading was 0.27 mmol/g, as calculated by Fmoc determination.

Fmoc-D-Val-OH (458 mg, 1.32 mmol, 5 equiv), Fmoc-Val-OH (360 mg, 1.06 mmol, 4 equiv), Fmoc-Thr(*t*Bu)-OH (527 mg, 1.32 mmol, 5 equiv), Fmoc-D-Val-OH (360 mg, 1.06 mmol, 4 equiv), and MeHex-OH (138 mg, 1.06 mmol, 4 equiv) were added sequentially to the above peptide resin using DIPCDI (165 μ L, for 1.06 mmol and 4 equiv; and 205 μ L, for 1.32 mmol and 5 equiv) and HOBt (162 mg, for 1.06 mmol and 4 equiv; and 203 mg, for 1.32 mmol and 5 equiv) for 90 min. In all cases, after 90 min of coupling, the ninhydrin test was negative. Removal of Fmoc group and washings were performed as described in General Procedures.

The partially protected peptide was cleaved from the resin by TFA-CH₂Cl₂ (1:99) (5 x 30 sec). Filtrate was collected on H₂O (4 mL) and H₂O was partially removed in a rotavapor. MeCN was then added to dissolve the solid that formed during H₂O removal, and the solution was lyophilized to give 154.4 mg (226 μ mol, 86 % yield) of the title compound with a purity of > 94 % as checked by HPLC (Column A, *R*_t 12.13 min). The crude obtained after evaporation showed a purity of > 94 %. The product was characterized by ES-MS. Calcd. for C₃₅H₆₃N₅O₈, 681.9. Found: *m/z* 682.15.

Kahalalide F: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val& from C- and N-Components 1

N-Component 1 (8.25 mg, 8.5 μ mol) and *C-Component 1* (7 mg, 10.2 μ mol, 1.2 equiv) were dissolved in DMF (10 mL) and PyAOP (5.32 mg, 10.2 μ mol, 1.2 equiv) and DIPEA (5.3 μ l, 30.6 μ mol, 3.6 equiv) were added at room temperature. The mixture was stirred for 1 h, when extra PyAOP (5.32 mg, 10.2 μ mol, 1.2 equiv) was added. The mixture was allowed to react for 2 h at room temperature until HPLC (Column A) showed completion of the reaction. HPLC showed that the crude obtained after evaporation had a purity of > 75 %.

The crude product was purified by HPLC (Symmetry C8 5 μ m, 30x 100 mm), linear gradient of MeCN (+0.05% TFA) in water (+0.05% TFA) (30% to 100% in 15 min), 20 mL/h, detection at 220 nm, to give the protected Kahalalide F (6.9 mg, 4.2 μ mol, 49% yield).

MALDI-TOF-MS, calcd. for C₈₄H₁₄₀N₁₄O₁₈, 1,633.05. Found: *m/z* 1,534.33 [M-Boc]⁺, 1,556.26 [M-Boc+Na]⁺ 1,656.33 [M+Na]⁺.

Protected Kahalalide F was dissolved in TFA–H₂O (19:1, 700 μL) and the mixture was stirred for 1 h. The solvent was removed by evaporation under reduced pressure and dioxane was added (245 μL). Again, the solvent was removed by evaporation under reduced pressure (the process was repeated three times), H₂O (1 mL) was then added and the solution was lyophilized. The crude product was purified by HPLC (Symmetry C8 5 μm, 30 x 100 mm), isocratic 44% MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title product (5 mg, 3.4 μmol, 80 % yield, 93.3%).

The HPLC of the crude product did not show the epimeric peptide MeHex-D-Val-Thr-Val-D-Val-Pro-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val& (**Epimer 1**). This observation indicates racemization during the coupling step between the two protected peptides. MALDI-TOF-MS, calcd. for C₇₅H₁₂₄N₁₄O₁₆, 1,476.93. Found: *m/z* 1,478.17 [M+H]⁺ 1,500.14 [M+Na]⁺, 1,516.12 [M+K]⁺.

Epimer 1: MeHex-D-Val-Thr-Val-D-Val-Pro-Orn-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val&

Experimental procedures were as described for the stepwise synthesis of Kahalalide F, except that Fmoc-D-Pro-OH was replaced by Fmoc-Pro-OH.⁸ The product was characterized by HPLC (*R*_t 11.23 min, Column A) and for MALDI-TOF-MS: calcd. C₇₅H₁₂₄N₁₄O₁₆, 1,476.93. Found: *m/z* 1,500.23 [M+Na]⁺, 1,515.97 [M+K]⁺.

***N*-Component 2: H-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-Phe-ZDhb-Val&**

Starting with [Fmoc-D-allo-Ile-D-allo-Thr(&)-D-allo-Ile-D-Val-O-TrtCl-resin][Alloc-Val&] (**2**), the Alloc group was removed with Pd(PPh₃)₄ (58 mg, 0.05 mmol, 0.1 equiv) in the presence of PhSiH₃ (617 μL, 5 mmol, 10 equiv) and the resin was washed with sodium diethyldithiocarbamate in DMF 0.02 M (3 x 15 min). Alloc-Phe-ZDhb-OH (666 mg, 2 mmol, 4 equiv) and HOAt (273 mg, 2 mmol, 4 equiv) were dissolved in DMF (1.25 mL) and added to peptidyl-resin. DIPCDI (310 μL, 2 mmol, 4 equiv) was then added and the

mixture was stirred for 5 h; at which point the HPLC showed completion of reaction (R_t 7.09 min, Column A).

The Fmoc group was removed and after extensive DMF washings, Boc_2O (546 mg, 5 equiv) and DIPEA (0.87 mL, 10 equiv) in DMF were added and left to react for 2 h. The ninhydrin test was negative at this time point.* After DMF washings, the Alloc group was removed and the protected peptide was cleaved from the resin with TFA- CH_2Cl_2 (1:99) (5 x 30 sec). Filtrate was collected on H_2O (4 mL) and H_2O was partially removed under reduced pressure. MeCN was then added to dissolve the solid that formed during H_2O removal and the solution was then lyophilized.

Cyclization was performed as for compound **6** and Boc was then removed with TFA- H_2O (19:1) (1 h). The solvent was removed under reduced pressure and dioxane was added (245 μL). Again, the solvent was removed by evaporation under reduced pressure (the process was repeated three times), and then H_2O (1 mL) was added and lyophilized. The crude product was purified by HPLC (Symmetry C8 5 μm , 30 x 100 mm), isocratic 44% MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title product (207 mg, 273 μmol , 55 % yield, 93.3%). The product was characterized by HPLC (R_t 7.27 min, Column A) and for MALDI-TOF-MS: calcd. $\text{C}_{39}\text{H}_{61}\text{N}_7\text{O}_8$, 755.46. Found: m/z 756.56 $[\text{M}+\text{H}]^+$, 778.55 $[\text{M}+\text{Na}]^+$, 794.53 $[\text{M}+\text{K}]^+$.

C-Component 2: MeHex-D-Val-Thr(*t*Bu)-Val-D-Val-D-Pro-Orn(Boc)-OH

Experimental procedures as for *C-Component 1*, except that the peptide synthesis was initiated by incorporation of Fmoc-Orn(Boc)-OH to the Cl-TrtCl-resin. The product was characterized by HPLC (R_t 13.27 min, Column A) and for Electrospray. Calcd $\text{C}_{45}\text{H}_{81}\text{N}_7\text{O}_{11}$, 895,60. Found: m/z 895,10 .

Kahalalide F: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val& from C- and N-Components 2

* Alternatively, Boc-D-*allo*-Ile-OH can be introduced instead of the Fmoc derivative.

The synthesis was performed as described above except that the condensed fragments were *N-Component 2* and *C-Component 2*. The HPLC of the crude final product showed the presence of the epimeric peptide MeHex-D-Val-Thr-Val-D-Val-D-Pro-D-Orn-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val& (4.1%) (Epimer 2), which indicates racemization during the coupling step between both protected peptides. The product was characterized by HPLC (R_t 10.5 min, Column A). MALDI-TOF-MS, calcd. $C_{75}H_{124}N_{14}O_{16}$, 1,476.93. Found: m/z 1,477.99 $[M+H]^+$ 1,499.97 $[M+Na]^+$, 1,515.93 $[M+K]^+$.

Epimer 2: MeHex-D-Val-Thr-Val-D-Val-D-Pro-D-Orn-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val&

The synthesis was carried out as described for the stepwise synthesis of Kahalide except that Fmoc-Orn(Boc)-OH is replaced by Fmoc-D-Orn(Boc)-OH.⁸ The product was characterized by HPLC (R_t 9.89 min, Column A). MALDI-TOF-MS, calcd $C_{75}H_{124}N_{14}O_{16}$, 1,476.93. Found: m/z 1,478.06 $[M+H]^+$ 1,500.15 $[M+Na]^+$, 1,516.04 $[M+K]^+$.

N-Component 3: H-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val&

Starting with Fmoc-D-*allo*-Thr-D-*allo*-Ile-D-Val-Phe-ZDhb-O-TrtCl-resin, the Fmoc group was removed and after extensive DMF washings, Boc_2O (546 mg, 5 equiv) and DIPEA (0.87 mL, 10 equiv) in DMF were added and left to react for 2 h, after which the ninhydrin test was negative. After DMF washings, Fmoc-Val-OH (848.2 mg, 2.5 mmol, 5 equiv) was coupled with DIPCDI (387 μ L, 2.5 mmol, 5 equiv) in the presence of DMAP (30.6 mg, 0.25 mmol, 0.5 equiv) and DIPEA (88 μ L, 0.5 mmol, 1 equiv) for 45 min. This coupling was repeated in the same conditions twice. After removal of the Fmoc group as described in General Procedures, the protected peptide was cleaved from the resin by TFA- CH_2Cl_2 (1:99) (5 x 30 sec). Filtrate was collected on H_2O (4 mL) and the H_2O was partially removed under reduced pressure. MeCN was then added to dissolve the solid that appeared during the H_2O removal, and the solution was lyophilized, to give 57 mg (75 μ mol, 90% yield) of the title compound with a purity of > 95 %, as checked by HPLC (Column A, R_t 7.95 min). ESMS, calcd. for $C_{38}H_{60}N_6O_{10}$, 760.44. Found: m/z 762.3 $[M+H]^+$.

Cyclization was carried out as for compound **6**, and the Boc was then removed with TFA–H₂O (19:1) (1 h). The solvent was removed under reduced pressure and dioxane was added (245 μL). The solvent was removed by evaporation under reduced pressure (the process was repeated three times), and then H₂O (1mL) was added and lyophilized. The crude product was purified by HPLC (Symmetry C8 5 μm, 30 x 100 mm), isocratic 30 % MeCN (+0.05% TFA) in water (+0.05% TFA), 20 mL/h, detection at 220 nm, to give the title product (50.2 mg, 67.6 μmol, 90 % yield).

The product was characterized by HPLC (*R*_t 5.32 min, Column A) and for ES-MS, calcd. C₃₃H₆₁N₆O₉, 642.37. Found: *m/z* 642.035.

C-Component 3: MeHex-D-Val-Thr(*t*Bu)-Val-D-Val-D-Pro-Orn(Boc)-D-*allo*-Ile-OH

Experimental procedures as for the obtention of *C-Component 1*, except that the peptide synthesis was initiated by incorporation of Fmoc-D-*allo*-Ile-OH to the Cl-TrtCl-resin. The product was characterized by HPLC (*R*_t 10.25 min, Column A) and for MALDI-TOF-MS, calcd. C₅₁H₉₂N₈O₁₂, 1,008.68. Found: *m/z* 1,009.8.

Kahalalide F: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-D-*allo*-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val& from *C*- and *N*-Components 3

Experimental procedures were as described for the other syntheses of Kahalalide F. The HPLC of the final product showed the presence of the epimeric peptide MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-Ile-D-*allo*-Thr(&)-D-*allo*Ile-D-Val-Phe-ZDhb-Val& (Epimer 3), which indicates racemization during the coupling step between the two protected peptides. The product was characterized by HPLC (*R*_t 7.92 min, Column A). MALDI-TOF-MS, calcd. C₇₅H₁₂₄N₁₄O₁₆, 1,476.93. Found: *m/z* 1,478.5 [M+H]⁺ 1,501.4 [M+Na]⁺, 1,517.6 [M+K]⁺.

Epimer 3: MeHex-D-Val-Thr-Val-D-Val-D-Pro-Orn-Ile-D-*allo*-Thr(&)-D-*allo*-Ile-D-Val-Phe-ZDhb-Val&

Experimental procedures were as described for the stepwise synthesis of Kahalaide F, except that Fmoc-Ile-OH was used instead of Fmoc-D-*allo*-Ile-OH.⁸ MeHex-D-Val-Thr(*t*Bu)-Val-D-Val-D-Pro-Orn(Boc)-Ile-OH: (R_t 10.25 min, Column A and MALDI-TOF-MS, calcd. $C_{51}H_{92}N_8O_{12}$, 1,008.68. Found: m/z 1,009.5). The final product was characterized by HPLC (R_t 8.02 min, Column A). MALDI-TOF-MS, calcd. $C_{75}H_{124}N_{14}O_{16}$, 1,476.93. Found: m/z 1,478.2 $[M+H]^+$, 1,501.1 $[M+Na]^+$, 1,517.3 $[M+K]^+$.

Acknowledgments. This study was partially supported by CICYT (BQU 2003-00089), the *Generalitat of Catalunya*, and the Barcelona Science Park. AI thanks the *DURSI, Generalitat de Catalunya* and Europea Social Funds for a predoctoral fellowship.

References

- ¹ Hamann, M. T.; Scheuer, P.J. *J. Am. Chem. Soc.*, **1993**, *115*, 5825-5826.
- ² Hamann, M. T. *Curr. Opin. Mol. Ther.* **2004**, *6*, 657-665.
- ³ Janmaat, M. L.; Rodriguez, J. A.; Jimeno, J.; Kruyt, F. A. E.; Giaccone, Giuseppe. *Mol. Pharmacol.*, **2005**, *68*, 502-510.
- ⁴ Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Muñoz, A.. *Mol. Cancer Ther.*, **2003**, *2*, 863-872.
- ⁵ Jimeno, J.; Faircloth, G.; Fernandez Souse-Faro, J. M.; Scheuer, P.; Rinehart, K. *Mar. Drugs*, **2004**, *2*, 14-29.
- ⁶ Izquierdo Delso, M. A. PCT Int. Appl. (2004), WO 2004075910 A1 20040910 CAN 141:236712 AN 2004:740175.
- ⁷ Goetz, G.; Yoshida, W. Y.; Scheuer, P. J. *Tetrahedron* **1999**, *55*, 7739-7746 and 11957.
- ⁸ Lopez-Macia, A.; Jimenez, J. C.; Royo, M.; Giralt, E.; Albericio, F. *J. Am. Chem. Soc.* **2001**, *123*, 11398-11401.

-
- ⁹ Bonnard, I.; Manzanares, I.; Rinehart, K. L. *J. Nat. Prod.*, **2003**, *66*, 1466-1470.
- ¹⁰ Albericio, F.; Fernandez, A.; Giralt, E.; Gracia, C.; Lopez, P.; Varon, S.; Cuevas, C.; Lopez-Macia, A.; Francesch, A.; Jimenez, J. C.; Royo, M. *PCT Int. Appl.* **2005**, WO 2005023846 A1 20050317 CAN 142:298335 AN 2005:239012.
- ¹¹ Lopez, P. E.; Isidro-Llobet, A.; Gracia, C.; Cruz, L. J.; Garcia-Granados, A.; Parra, A.; Alvarez, M.; Albericio, F. *Tetrahedron Lett.* **2005**, *46*, 7737-7741.
- ¹² (a) Lloyd-Williams, P.; Albericio, F.; Giralt, E. *Tetrahedron.* **1993**, *49*, 11065-11133; (b) Lloyd-Williams, P.; Albericio, F.; Giralt, E. "Chemical approaches to the synthesis of peptides and proteins". CRC Press. Boca Raton (FL), 1997.
- ¹³ Benz, H. *Synthesis*, **1994**, (4), 337-58.
- ¹⁴ (a) Barlos, K.; Gatos, D. *Biopolymers* **1999**, *51*, 266-278; (b) Barlos, K.; Gatos, D. In *Fmoc Solid Phase Peptide Synthesis* Editor(s): Chan, Weng C.; White, Peter D. (2000), 215-228. Publisher: Oxford University Press, Oxford, UK
- ¹⁵ Sakakibara, S. *Biopolymers*, **1999**, *51*, 279-296.
- ¹⁶ An orthogonal protecting scheme is defined as one based on completely different classes of protecting groups such that each class of groups can be removed in any order and in the presence of all other classes of protecting groups. Barany, G.; Albericio, F. *J. Am. Chem. Soc.*, **1985**, *107*, 4936-4942.
- ¹⁷ Fields, G.B. *Methods in Enzymology, Solid-Phase Peptide Synthesis*, Vol. 289; Academic Press: Orlando, Florida, 1997.
- ¹⁸ Goodman, M.; Felix, A.; Moroder, L.; Toniolo, C. *Houben-Weyl. Methods of Organic Chemistry*, Vol. E 22, *Synthesis of Peptides and Peptidomimetics*; Georg Thieme Verlag: Stuttgart, Germany, 2001.
- ¹⁹ Bruckdorfer, T.; Marder, O.; Albericio, F. *Curr. Pharm. Biotech.* **2004**, *5*, 29-43.

-
- ²⁰ Albericio, F. *Curr. Opin. Chem. Biol.* **2004**, *8*, 211–221.
- ²¹ Nishiuchi, Y.; Inui, T.; Nishio, H.; Bodi, J.; Kimura, T.; Tsuji, F. T.; Sakakibara, S.. *P Natl. Acad Sci. USA*, **1998**, *95*, 13549-13554.
- ²² Chiva, C.; Barthe, P.; Codina, A.; Gairi, M.; Molina, F.; Granier, C.; Pugniere, M.; Inui, T.; Nishio, H.; Nishiuchi, Y.; Kimura, T.; Sakakibara, S.; Albericio, F.; Giralt, E. *J. Am. Chem. Soc.*, **2003**, *125*, 1508-1517.
- ²³ Bray, Brian L. *Nat. Rev. Drug Discov.*, **2003**, *2*, 587-593.
- ²⁴ (a) Barlos, K.; Gatos, D.; Schäfer, W. *Angew. Chem. Int. Ed. Engl.* **1991**, *30*, 590-593; (b) Barlos, K.; Chatzi, O.; Gatos, D.; Stavropoulos G. *Int. J. Pept. Prot. Res.*, **1991**, *37*, 513-520.
- ²⁵ Rovero, P.; Vigano, S.; Pegoraro, S.; Quartara, L. *Lett. in Pept. Sci.*, **1996**, *2*, 319-323.
- ²⁶ Chiva, C.; Vilaseca, M.; Giralt, E.; Albericio, F. *J. Pept. Sci.* **1999**, *5*, 131-140.
- ²⁷ If the loading is greater than 1 mmol/g, as most of the commercial available resins of this kind are, the analysis by HPLC-ESMS of the crude product shows additional peaks, corresponding to terminated sequences. (see ref. 26).
- ²⁸ Garcia-Martin, F.; Bayo, N.; Cruz, L.J.; Tulla, J.; Bohling, J.; Albericio, F. Manuscript in preparation.
- ²⁹ Isidro-Llobet, A.; Guasch-Camell, J.; Alvarez, M.; Albericio, F. *Eur. J. of Org. Chem.*, **2005**, pp. 3031-3039.
- ³⁰ Isidro-Llobet, A.; Alvarez, M.; Albericio, F. *Tetrahedron Lett.* **2005**, *46*, 7733-7736.
- ³¹ The synthesis of peptides by convergent approaches and/or the cyclic peptides require the use of semipermanent protecting groups, which must be stable to the conditions used to remove the temporal protecting group, which are those that are removed after each synthetic cycle and should be removed without affecting any permanent protecting groups, which removed in the final step of the synthetic process: Albericio, F. *Biopolymers*, **2000**, *55*, 123-139.

³² Guibe, F. *Tetrahedron*. **1997**, 53(40), 13509-13556 and *Tetrahedron* **1998**, 54, 2967-3042.

³³ It is interesting to point out that the ester bond between DaThr⁶ and LVal¹ is perfectly stable to the repetitive piperidine treatments during the stepwise elongation of the peptidic chain where the cycle is still not formed, the same ester bond is unstable to just one piperidine treatment once the cycle is already formed. This is an illustrative example of that the rigidity conferred by a cycle can change the physicochemical properties of a molecule.

³⁴ Albericio, F.; Bofill, J. M.; El-Faham, A.; Kates, S. A. *J. Org. Chem.* **1998**, 63, 9678-9683.

³⁵ Carpino, L.A.; El-Faham, A.; Minor, C.A.; Albericio, F. *J. Chem. Soc., Chem. Commun.* **1994**, 201-203.

³⁶ These epimers did not show any remarkable biological activity in the typical cell lines used for evaluation the antitumor activity of Kahalalide F and its analogues.

³⁷ Dangles, O.; Guibe, F.; Balavoine, G.; Lavielle, S.; Marquet, A. *J. Org. Chem.* **1987**, 52, 4984-4993.

³⁸ Cruz, L. J.; Beteta, N. G.; Ewenson, A.; Albericio, F.; *Org. Process Res. Dev.* **2004**, 8, 920-924.

³⁹ Albericio, F.; Giralt, E.; Jimenez, J. C.; Lopez, A.; Manzanares, I.; Rodrigues, I.; Royo, M. *PCT Int. Appl.* (2001), WO 2001058934 A2 20010816 CAN 135:167039 AN 2001:598019.

⁴⁰ Spengler, J.; Jimenez, J.C.; Burger, K.; Giralt, E.; Albericio, F. *J. Pept. Res.* **2005**, 65, 550-555.

SYNOPSIS TOC

